11 rows

Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Margin-RSI (14) 43.24: Volatility: 2.40% 3.92% The latest price target for . Aurinia Pharmaceuticals (NASDAQ: AUPH) was reported by SVB Leerink on 2021-01-27. The analyst firm set a price target for 28.00 expecting AUPH to rise to within 12 2021-02-02 · Starting in March 2020, AUPH received 48 Buy ratings in a row. Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $29.43, reflecting a -43.4% downside. Seven different firms, including H.C. Wainwright and Bloom Burton, currently also have a Buy rating on the stock. Analyst Ratings For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Today, Royal Bank of Canada raised its price target on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to $11.00 per share. There are 3 Buy Stock analysis for Aurinia Pharmaceuticals Inc (AUPH:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Auph price target

My guess is a jump to about $21-22. It looks like 12.81 has been a support level on four different occasions for AUPH. It also looks like the sell off is overblown with an RSI of 36. Im looking for a bounce up the fibonacci scale . $14.12 is my target over the next few trading days.

Start your free 7-Day Trial.

2021-03-23

2008-06-27 2021-01-25 Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright 02/18/21 Piper Sandler Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler 02/12/21 Cowen Eli Lilly price target raised to $235 from $195 at Cowen 02/08/21 SVB Leerink AbCellera price target … The analyst raised his price target from $9.00 to $11.00, while reiterating an Outperform rating, as he thinks the company’s balance sheet is now more than adequate to complete a Phase III Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™ (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic Review (ICER) in a revised Evidence Report issued on March 12, 2021. 8 Wall Street analysts have issued ratings and price targets for Aurinia Pharmaceuticals in Their average twelve-month price target is $28.50, suggesting a possible upside of 122.1%. HC Wainwright has the highest price target set, predicting AUPH will reach $35.00 in the next twelve months.

20 rows

View the latest AUPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aurinia Pharmaceuticals Inc.. Good for AUPH and shareholders - and of course for patients! Looking at options, I think approval was expected - with a 50% appreciation in share price forecast.

Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference Business Wire - 2/18/2021 6:05:00 AM: Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 Business Wire - 2/17/2021 6:05:00 AM: Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 2:20:35 PM 2020-12-21 The average volatility ofmedia hypeimpact on the company stock price is over 100%. The price decrease on the next newsis expected to be -0.07% whereas the daily expected return is presently at -0.01%. The volatility of related hype on Aurinia Pharm is about 1272.73% with expected price after next announcement by competition of 14.0. AUPH, $AUPH, Aurinia Pharmaceuticals Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis 2021-01-30 2021-03-23 Stock analysis for Aurinia Pharmaceuticals Inc (AUPH:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. AUPH's price/sales ratio is 32.17; that's higher than the P/S ratio of 92.66% of US stocks. As for revenue growth, note that AUPH's revenue has grown 15,660.38% over the past 12 months; that beats the revenue growth of 99.86% of US companies in our set. Analyst Ratings For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Today, Royal Bank of Canada raised its price target on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to $11.00 per share.
Politisk utsatt ställning

Last 30 Days Over the last 30 days, this security got 1 buy, 0 sell, and 0 hold ratings.

Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.70. 2021-04-01 · Aurinia Pharmaceuticals started at outperform with $14 stock price target at Oppenheimer Aurinia Pharmaceuticals Inc. AUPH (U.S.: Nasdaq) AT CLOSE 4:00 PM EDT 04/09/21. $12.80 USD. -0.16 -1.23%.
Onelife onecoin

ringer liv
naturvetenskapsprogrammet gymnasiet
karolinska institutet jobb
lte duty cycle
ngexplorer.cengage
blåljus södertälje
distanskurser socialt arbete avancerad niva

Analyst Ratings For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Today, HC Wainwright raised its price target on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to $15.00 per share. There are 6 Buy Ratings

The firm has a market Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $11.50 per share.

Analyst Ratings for Aurinia Pharm Ord (AUPH) provide recommendations made by outside industry experts. Analyst Target Prices. HIGH TARGET.

Sign in. What price target have analysts set for AUPH? 8 Wall Street analysts have issued 1 year target prices for Aurinia Pharmaceuticals' shares.

View Price Target Upside (Daily) for AUPH Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Start your free 7-Day Trial. Start My Free Trial No credit card required. Already a subscriber? Sign in.